Health & MedicineBreaking NewsBreakingLatest News
Cancer Drug Prices Fall by Up to 96%, Patients to Save Rs 3,540 Crore
Sentiment: NeutralHigh Priority
What Happened?
Starting today, prices of several anti-cancer drugs in India have dropped significantly, with some reductions reaching 96%. This move is expected to save patients over Rs 3,540 crore annually.
Key points
- The NPPA has capped trade margins on 137 non-scheduled anti-cancer drugs at 30%.
- 85 pharmaceutical companies have reported revised maximum retail prices for 1,364 formulations.
- 679 brands have reported price reductions exceeding 50%, with the highest cut at 96.45%.
- Zydus Lifesciences' bevacizumab brand price fell from Rs 25,995 to Rs 3,318.
- Patients using expensive patented therapies may not see similar price reductions.
Key insights
- The price cuts may lead to increased accessibility of essential cancer medications for many patients.
- Patients relying on out-of-pocket payments could benefit significantly from lower drug prices.
- The NPPA's intervention highlights ongoing concerns about the affordability of cancer treatments in India.
Why it matters
This price reduction could significantly alleviate the financial burden on cancer patients and their families.
Source
India Today
